Pete,  I think he's mentioning twice weekly for future phases, rather than doing this in the current Ph1 trial.  So, that might be part of a protocol design for PH2 or PH3, trying various dosing cycles from the start of the trial.

We believe the dose for efficacy in humans to be about 100mg/m2 to 200mg/m2. It is important to note that in the next phases it could be determined if it is best to dose twice a week. We are now dosing 50 and could achieve 100 in the next cohort.